The Pathogenesis and Management of Hypertension in Diabetic Kidney Disease

Medical Clinics of North America

Volumn 97, Issue 1, 2013, Pages 31-51

  Van Buren, Peter N ^a   Toto, Robert D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ACE inhibitor; Hyperkalemia; Hypertension; RAAS therapy; Vasoconstriction

Indexed keywords

ALISKIREN; ANGIOTENSIN[1-7]; ANTIHYPERTENSIVE AGENT; ATRESENTAN; AVOSENTAN; BENAZEPRIL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; SPIRONOLACTONE; UNCLASSIFIED DRUG; VALSARTAN;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SODIUM ABSORPTION; VASOCONSTRICTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; OUTCOME ASSESSMENT (HEALTH CARE); OXIDATIVE STRESS; PREVALENCE; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM;

EID: 84871815571     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.10.003     Document Type: Review

References (103)

1. Parving H., Gall M., Skott P., et al. Prevalence and causes of albuminuria in non insulin-dependent diabetic patients. Kidney Int 1992, 4:758-762.
2. Chobanian A., Bakris G., Black H., et al. The Seventh Report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure. J Am Med Assoc 2003, 289:2560-2572.
3. American Diabetes Association Treatment of hypertension in adults with diabetes. Diabetes Care 2003, 26:S80-S82.
4. National Kidney Foundation KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49(Suppl 2):S1-S180.
5. Norgaard K., Feldt-Rasmussen B., Johnsen K., et al. Prevalence of hypertension in type 1 (insulin dependent) diabetes mellitus. Diabetologia 1990, 33:407-410.
6. Parving H., Hommel E., Mathiesen E., et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988, 296:156-160.
7. Lurbe E., Redon J., Kesani A. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002, 347:797-805.
8. Haffner S., Mykkanen L., Festa A., et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000, 101:975-980.
9. Keller C., Bergis K., Filser D., et al. Renal findings in patients with short term type 2 diabetes. J Am Soc Nephrol 1996, 7:2627-2635.
10. Ismail N., Becker B., Strzelczyk P., et al. Renal disease and hypertension in non-insulin dependent diabetes mellitus. Kidney Int 1999, 55:1-28.
11. Hypertension in Diabetes Study Investigators Hypertension in Diabetes Study (HDS): II, increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993, 11:319-325.
12. Mogensen C. Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus. Scand J Clin Lab Invest 1971, 28:91-100.
13. Vallon V., Richter K., Blantz R., et al. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 1999, 10:2569-2576.
14. Brands M., Bell T., Gibson B. Nitric oxide may prevent hypertension early in diabetes by counteracting renal actions of superoxide. Hypertension 2004, 43:57-63.
15. Veelken R., Hilgers K., Hartner A., et al. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol 2000, 11:71-79.
16. Tuck M., Corry D., Trujillo A. Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus. Am J Hypertens 1990, 88:210-216.
17. Anderson F., Jung F., Ingelfinger J. Renal rennin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biologic correlations. Am J Physiol 1993, 265(4 Pt 2):F477-F486.
18. Konoshita T., Wakahara S., Mizuno E.A. Tissue gene expression of rennin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 2006, 29:848-852.
19. Mizuiri S., Yoshikawa H., Tanegashima M., et al. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis 1998, 31:301-307.
20. Mezzano S., Droguett A., Burgos M., et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl 2003, 86:S64-S70.
21. Price D., Porter L., Gordon M. The paradox of the low renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382.
22. Price D., De'Oliveira J., Fisher N., et al. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type 2 diabetes mellitus. Am J Hypertens 1999, 12:348.
23. Giani J., Burghi V., Veiras L., et al. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 2012, 302:F1606-F1615.
24. Ye M., Wysocki J., William J., et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006, 17:3067-3075.
25. Lely A., Hamming I., van Goor H., et al. Renal ACE2 expression in human kidney disease. J Pathol 2004, 204:587-593.
26. Mizuiri S., Hemmi H., Arita M., et al. Expressio of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008, 51:613-623.
27. Soro-Paavonen A., Gordin D., Forsblom C., et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 2012, 30:375-383.
28. Dogra G., Irish A., Chan D., et al. Insulin resistance, inflammation, and blood pressure determine vascular function in CKD. Am J Kidney Dis 2006, 48:926-934.
29. Makino H., Doi K., Hiuge A., et al. Impaired flow-mediated vasodilation and insulin resistance in type 2 diabetic patients with albuminuria. Diabetes Res Clin Pract 2008, 79:177-182.
30. Chan W., Chan N., Lai C., et al. Vascular defect beyond the endothelium in type II diabetic patients with overt nephropathy and moderate renal insufficiency. Kidney Int 2006, 70:711-716.
31. Giugliano D., Marfella R., Coppola L., et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997, 95:1783-1790.
32. Fitzgerald S., Brands M. Nitric oxide may be required to prevent hypertension at the onset of diabetes. Am J Phys 2000, 279:E762-E768.
33. Achan V., Broadhead M., Malaki M., et al. Asymetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethyl dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003, 23:1455-1459.
34. Kielstein J., Boger R., Bode-Boger S. Asymetric dimethylarginine concentrations differ in patients with end stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999, 10:594-600.
35. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
36. Tarnow L., Hovind P., Teerlink T., et al. Elevated plasma asymetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004, 27:765-769.
37. Abbasi F., Asagmi T., Cooke J., et al. Plasma concentrations of asymetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001, 88:1201-1203.
38. Kakizawa H., Itoh M., Itoh Y., et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 2004, 53:550-556.
39. Minchenko A., Stevens M., White L., et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly (ADP-ribose) polymerase activation. FASEB 2003, 17:1514-1516.
40. Muniyappa R., Quon M. Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care 2007, 10:523.
41. Rafnsson A., Bohm F., Settergren M., et al. The endothelin receptor antagonist bosentan improves peripheral endothelial cell function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia 2012, 55:600-607.
42. Rajagopalan S., Kurz S., Munzel T., et al. Angiotensin II-mediated hypertension in the rate increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996, 97:1916-1923.
43. Griendling K., Ollernenshaw J., Minieri C., et al. Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells. Circ Res 1994, 74:1141-1148.
44. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
45. Spittle M., Hoenich N., Handelman G., et al. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001, 38:1408-1413.
46. Ceballos-Picot I., Wtiko-Sarsat V., Merad-Boudia M., et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996, 21:845-853.
47. Campese V., Kogosove E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995, 25:878-882.
48. Converse R., Jacobsen T., Toto R., et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327:1912-1918.
49. Ligtenberg G., Blankestijn P., Oey P., et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999, 340:1321-1328.
50. Spallone V., Gambardella S., Maiello M., et al. Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients. Diabetes Care 1994, 17:578-584.
51. Liniger C., Favre L., Assal J. Twenty-four hour blood pressure and heart rate profiles of diabetic patients with abnormal cardiovascular reflexes. Diabet Med 1991, 8:420-427.
52. Nielsen F., Hansen H., Jacobsen P. Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. Diabet Med 1999, 16:555-562.
53. Zoppini G., Targher G., Choncol M., et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 2012, 7:401-408.
54. Berhane A., Weil E., Knowler W., et al. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clin J Am Soc Nephrol 2011, 6:2444-2451.
55. Mogensen C. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982, 285:685-688.
56. Parving H., Smidt U., Andersen A., et al. Early aggressive anithypertensive treatment reduces rate of decline of kidney function in diabetic nephropathy. Lancet 1983, 321:1175-1179.
57. Parving H., Andersen A., Smidt U., et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987, 294:1443-1447.
58. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
59. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
60. Lindholm L., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
61. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329(20):1456-1462.
62. Parving H.H., Hommel E., Jensen B.R., et al. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001, 60(1):228-234.
63. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345(12):851-860.
64. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345(12):861-869.
65. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345(12):870-878.
66. Ruggenenti P., Fassi A., Ilieva A., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
67. Haller H., Ito S., Izzo J., et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011, 364:907-917.
68. Mauer M., Zinman B., Gardiner R., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40-51.
69. Bilous R., Chaturvedi N., Sjolie A., et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes. Ann Intern Med 2009, 151:11-20.
70. Jacobsen P., Andersen S., Jensen B., et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003, 14:992-999.
71. Rossing K., Jacobsen P., Pietraszek L., et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 2003, 26:2268-2274.
72. Andersen N., Poulsen P., Knudson S., et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. Diabetes Care 2005, 28:273-277.
73. ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
74. Mann J., Schmieder R., McQueen E.A. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008, 372:547-553.
75. Department of Veteran Affairs; Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy; VA NEPHRON-D Study: Nephropathy iN Diabetes Study. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000-[cited 2012 March 26]. Available at: Accessed on 26th March 2012. http://www.clinicaltrials.gov/ct2/show/NCT00555217.
76. Schjoedt K., Rossing K., Juhl T., et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005, 68:2829-2836.
77. Schjoedt K.J., Rossing K., Juhl T.R., et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006, 70(3):536-542.
78. Mehdi U., Adams-Huet B., Raskin P., et al. Addition of angiotensin receptor blockade or a mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641-2650.
79. Persson F., Rossing P., Schjoedt K., et al. Time course of the antiproteinuric and anithypertensive effects of the direct rennin inhibition in type 2 diabetes. Kidney Int 2008, 73:1419-1425.
80. Parving H., Persson F., Lewis J., et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
81. Persson F., Rossing P., Reinhard H. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009, 32:1873-1879.
82. Parving H., Brenner B., McMurray J., et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009, 24:1663-1671.
83. Aliskiren-containing medications: drug safety communication-new warning and contraindication. 2012. Available at: Accessed May 4, 2012. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm301120.htm%3Fsource=govdelivery.
84. Heerspink H., Holtkamp F., Parving H., et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012, 82:330-337.
85. Vegter S., Perna A., Postma M., et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012, 23:165-173.
86. Li Y., Kong J., Wei M., et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
87. 3-dependent regulation of the renin-angiotensin system in 1 alpha-hydroxylase knockout mice. Kidney Int 2008, 74:170-179.
88. Zhang Z., Sun L., Wang Y., et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008, 73:163-171.
89. de Zeeuw D., Agarwal R., Amdahl M., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
90. Jawa A., Nachimuthu M., Pendergrass M., et al. Impaired vascular reactivity in African American patients wtih type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin converting enzyme inhibitor therapy. J Clin Endocrinol Metab 2006, 91:31-35.
91. Wenzel R., Littke T., Kuranoff S., et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009, 20:655-664.
92. Mann J., Green D., Jamerson K., et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010, 21:527-535.
93. Kohan D., Pritchett Y., Molitch M., et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011, 22:763-772.
94. Miao Y., Ottenbros S., Laverman G., et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment. Hypertension 2011, 58:2-7.
95. Tanabe K., Lanaspa M., Kitagawa W., et al. Nicorandil as a novel therapy for advanced diabetic nephropathy in the e-NOS deficient mouse. Am J Physiol Renal Physiol 2012, 302:F1151-F1160.
96. Saijonmaa O., Metsarinne K., Fyhrquist F. Carvedilol and its metabolites suprress endothelin-1 production in endothelial cell culture. Blood Press 1997, 6:24-28.
97. Inrig J., Van Buren P., Kim C., et al. Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. Clin J Am Soc Nephrol 2012, 7:1300-1309.
98. Zepeda R., Castillo R., Rodrigo R., et al. Effect of Carvedilol and Nebivolol on Oxidative Stress-related Parameters and Endothelial Function in Patients with Essential Hypertension. Basic Clin Pharmacol Toxicol 2012, 111:309-316.
99. Hansson L., Zanchetti A., Carruthers S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
100. The ACCORD Study Group Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585.
101. Berl T., Hunsicker L.G., Lewis J., et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005, 16:2170-2179.
102. Bakris G.L., Weir M.R., Shanifar S., et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003, 163(13):1555-1565.
103. de Galan B., Perkovic V., Ninomiya T., et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009, 20:883-892.